N/A N=159 Food Insecurity, Food as Medicine, Hypertension
Food Insecurity · Hypertension
Primary: Change Systolic Blood Pressure — 9.39; .25 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=950 PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
Asthma
Primary: Forced Expiratory Volume in One Second (FEV1) Percent Predicted — 65.6; 66.0; 70; 69.5 percent predicted — p=0.447
N/A N=294 Cognitive Behavioral Therapy to Improve Work and Wellness in Veterans With Mental Illness
Posttraumatic Stress Disorders
Primary: Total Weeks Worked in Competitive Jobs — 7.07; 4.86 Weeks Worked
Phase 4 N=240 Parrying the Pitfalls of PrEP: Project PEACH
HIV · STI
Primary: Number of Men Who Discontinue Daily Oral PrEP — 18 Participants
N/A N=80 Quatera 700 vs. Centurion
Cataract
Primary: Central Corneal Thickness — 572.8; 565.6 microns
N/A N=112 Pharmacogenetic-guided Choice of Post-surgery Analgesics
Acute Pain · Post Operative Pain
Primary: Feasibility of Integrating a PGx Panel Test in the EMR With a Pharmacist Consult Note for Each Patient — 35; 0 Participants
Phase 2 N=200 Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
SARS (Severe Acute Respiratory Syndrome) · Coronavirus
Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio
N/A N=49 Brief Acceptance and Commitment Therapy for HIV-infected At-risk Drinkers
Treatment
Primary: Number of Drinking Days: Baseline (at Baseline) — 26.21; 21.20 Days
Phase 2 N=10 Zanubrutinib in Patients With IgG4-Related Disease
IgG4 Related Disease
Primary: Volume of the Submandibular Glands on PET-MRI — 12.7; 9.34; -3.37 cm^3 — p=< 0.001
N/A N=29 Dietary Triggers of Gastrointestinal Symptoms in IBS Patients
Irritable Bowel Syndrome
Primary: Number of Participants With Worsening Irritable Bowel Syndrome (IBS) Symptoms Based on IBS-SSS — 8; 10; 11 Participants
N/A N=179 Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
Chronic Lymphocytic Leukemia · Non-Hodgkin Lymphoma · Untreated Chronic Lymphocytic Leukemia
Primary: Progression-free Survival — 0.839; 0.893; 0.827 Proportion of participants
N/A N=291 A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries
Arterial Occlusive Diseases · Atherosclerosis · Vascular Diseases
Primary: Participant Quality-of-Life Changes Via EuroQol 5 Dimension (EQ-5D) Questionnaire. — 0.7; 0.9; 0.8; 60.9 score on a scale
Phase 2 N=92 Digital Therapeutic for Chronic Pain Feasibility Study
Chronic Pain
Primary: PROMIS Pain Interference Scale - Short Form 6b — 62.1; 62.1; 62.8; 60.8 T-score - difference scores between arms
Phase 2 N=6 Butyrate Adjuvant Therapy for Type 1 Diabetes
Type1diabetes
Primary: Insulin Sensitivity — 5.71; 6.02 mg/kg/min
N/A N=16 AT GOAL: Adopting Technology for Glucose Optimization and Lifestyle in Pregnancy
Type2Diabetes · Pregnancy in Diabetic
Primary: Feasibility: Number of Participants Who Complete the Study Within 24 Month Time Period — 8; 8 Participants